Key Highlights

  • AnaptysBio (ANAB) surged over the past year, closing at $69.81 per share on July 13.
  • The biotech firm shifted to an asset-light royalty model, relying on GSK’s Jemperli for revenue.
  • Laughing Water Capital added ANAB as a new position, with an average purchase price below $60.

A hedge fund’s strong quarterly performance has brought AnaptysBio into focus, illustrating the high-stakes nature of biotech investing. The firm’s shares have seen notable appreciation as it transitions to a royalty-based business model, a strategy that has gained traction among clinical-stage biotechs seeking to reduce operational costs while maintaining revenue streams.

What Happened

Laughing Water Capital reported a 39.8% net return for the second quarter, with year-to-date gains reaching approximately 33.6%. Among its top portfolio additions was AnaptysBio, a company developing therapies for autoimmune and inflammatory diseases. The company recently completed a taxable spinoff of its developmental drug assets, pivoting to an asset-light approach centered on royalties from GSK’s cancer treatment, Jemperli.

Market Impact

The fund’s performance has resonated within the biotech sector, where smaller companies have faced mixed results. The company’s ongoing dispute with GSK over commercial agreement terms introduces uncertainty, yet its strategic shift has drawn parallels to other biotechs that have adopted similar asset-light structures, often trading at elevated valuations.

What's Next

Analysts have suggested that a favorable resolution to the GSK dispute could position AnaptysBio for further gains, with some projections indicating potential upside under certain scenarios. Laughing Water Capital’s average purchase price below $60 signals confidence in the stock’s trajectory, though the company’s dependence on a single revenue source remains a critical consideration. The fund’s second-quarter results may encourage other investors to explore comparable royalty-based models, particularly in therapeutic areas like autoimmune and oncology, where partnerships play a pivotal role in valuation.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.